OTHER BALANCE SHEET DETAILS

12 Months Ended

Dec. 31, 2021

Balance Sheet Related Disclosures [Abstract]

Inventory

The components of inventory are summarized as follows:


	As of December 31,
(In thousands)	2021		2020
Raw materials	$	14,754	$	63,460
Work in process	100,942		16,149
Finished goods	7,005		12,693
Total inventory	$	122,701	$	92,302

As of December 31, 2021 and 2020, we had $36.3 million and $17.1 million of long-term inventory, respectively, included within other assets in our consolidated balance sheet as we anticipate it being consumed beyond our normal operating cycle. As of December 31, 2021, we had $7.1 million of capitalized inventory produced for commercial sale for products awaiting regulatory approval. As of December 31, 2020, there was no capitalized inventory for products awaiting regulatory approval.

Property, Plant and Equipment, Net

Property, plant and equipment, net consist of the following:


	As of December 31,
(In thousands)	2021		2020
Buildings	$	262,637	$	262,637
Leasehold improvements	152,045		149,505
Construction in progress	80,753		28,005
Laboratory equipment	61,351		48,930
Manufacturing equipment	43,739		41,089
Computer equipment and software	21,885		19,064
Furniture and fixtures	10,883		11,066
Land	9,080		9,080
	642,373		569,376
Less: accumulated depreciation	(140,415)		(104,347)
Total	$	501,958	$	465,029

Accrued Expenses

Accrued expenses consist of the following:


	As of December 31,
(In thousands)	2021		2020
Product rebates and discounts	$	131,279	$	94,242
Compensation and related	93,583		97,433
Pre-clinical, clinical trial and manufacturing	83,534		46,506
Licensing and collaboration agreements	22,843		15,424
Consulting and professional services	17,784		11,501
Contingent liabilities	—		41,216
Other	46,151		49,587
Total	$	395,174	$	355,909

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our consolidated balance sheets that sum to the total of these amounts shown in the consolidated statements of cash flows:


	As of December 31,
(In thousands)	2021		2020		2019
Cash and cash equivalents	$	819,975	$	496,580	$	547,178
Total restricted cash included in other assets	2,178		2,466		2,450
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows	$	822,153	$	499,046	$	549,628

Accumulated Other Comprehensive (Loss) Income

The following table summarizes the changes in accumulated other comprehensive (loss) income, by component:


(In thousands)	Loss on Investment in Joint Venture		Defined Benefit Pension Plans, Net of Tax		Unrealized Gains (Losses) from Debt Securities		Foreign Currency Translation Adjustment		Total Accumulated Other Comprehensive (Loss) Income
Balance as of December 31, 2019	$	(32,792)	$	(3,520)	$	137	$	(343)	$	(36,518)
Other comprehensive loss before reclassifications	—		(531)		(14)		(7,081)		(7,626)
Amounts reclassified from other comprehensive income	—		297		225		—		522
Net other comprehensive (loss) income	—		(234)		211		(7,081)		(7,104)
Balance as of December 31, 2020	(32,792)		(3,754)		348		(7,424)		(43,622)
Other comprehensive income before reclassifications	—		899		—		11,398		12,297
Amounts reclassified from other comprehensive income	—		44		(1,978)		—		(1,934)
Net other comprehensive income (loss)	—		943		(1,978)		11,398		10,363
Balance as of December 31, 2021	$	(32,792)	$	(2,811)	$	(1,630)	$	3,974	$	(33,259)